Tiny but toxic: MBL researchers discover a mechanism of neurodegeneration in Alzheimer's disease

March 27, 2009

WOODS HOLE, MA-Tiny, toxic protein particles severely disrupt neurotransmission and inhibit delivery of key proteins in Alzheimer's disease, two separate studies by Marine Biological Laboratory (MBL) researchers have found.

The particles are minute clumps of amyloid beta, which has long been known to accumulate and form plaques in the brain of Alzheimer's patients.

"These small particles that haven't aggregated into plaques-these are increasingly being seen as the really toxic species of amyloid beta," says Scott Brady of University of Illinois College of Medicine, who has been an MBL investigator since 1982.

Brady and his colleagues found that these particles inhibit neurons from communicating with each other and with other target cells in the body.

"The disease symptoms for Alzheimer's are associated not with the death of the neurons - that is a very late event - but with the loss of functional connections. It's when the neuron is no longer talking to its targets that you start to get the memory deficits and dementia associated with the disease," Brady says.

The amyloid beta particles activate an enzyme, CK2, which in turn disrupts the "fast axonal transport" system inside the neuron, Brady found. This transport system has motor proteins that move various kinds of cargo (including neurotransmitters and the associated protein machinery for their release) from place to place in the neuron on microtubule tracks.

Brady's findings are complemented by a new study by Rudolfo Llinás of New York University School of Medicine. Brady and Llinás both conduct neuroscience research at the MBL using the giant nerve cell of the Woods Hole squid, Loligo paeleii, as a model system.

Llinás found that activation of CK2 blocks neurotransmission at the synapse - the point where the neuron connects to its target.

"Disruptions in the fast axonal transport system are probably key elements in the pathogenesis of Alzheimer's and other adult-onset neurodegenerative diseases, such as Parkinson's and ALS," says Brady. "It doesn't mean that is the only thing going on, or that it is the triggering feature of the disease. But we do know that changes in the fast axonal transport system are sufficient to cause the 'dying back' of neurons that is characteristic of these diseases."

The new findings suggest the possibility of designing a drug to inhibit CK2 activation in Alzheimer's patients. However, a prior study by Brady found that activation of another enzyme, GSK3, in Alzheimer's also disrupts the fast axonal transport system. It may therefore be necessary to inhibit both enzymes.

"There haven't yet been any therapies designed for Alzheimer's with the idea of protecting the fast axonal transport system," says Brady. "But if there were, they would have to inhibit the activation of both CK2 and GSK3. We can't think of it as a single thing going wrong. There are several things going wrong."

Marine Biological Laboratory

Neurodegeneration: The Molecular Pathology of Dementia and Movement Disorders
by Dennis Dickson (Editor), Roy O. Weller (Editor)

Most textbooks on neurodegenerative disorders have used a classification scheme based upon either clinical syndromes or anatomical distribution of the pathology. In contrast, this book looks to the future and uses a classification based upon molecular mechanisms, rather than clinical or anatomical boundaries. Major advances in molecular genetics and the application of biochemical and immunocytochemical techniques to neurodegenerative disorders have generated this new approach. Throughout most of the current volume, diseases are clustered according to the proteins that accumulate within cells (e.g. tau, α-synuclein and TDP-43) and in the extracellular compartments (e.g. β-amyloid and prion proteins) or according to a shared pathogenetic mechanism, such as trinucleotide repeats, that...

Metal-based Neurodegeneration: From Molecular Mechanisms to Therapeutic Strategies
by Professor Robert Crichton (Author), Professor Roberta Ward (Author)

This exciting new book opens a window into the causes of debilitating neurological disorders such as Parkinson’s disease, CJD and Huntington’s disease, and gives indications of the prospects for therapy, based on the understanding of molecular defects involved in these diseases.Looking at each specific neurological disorder in turn, the book outlines the role of metals in human biology, in particular in the brain and explores tools for testing potential therapeutic strategies. It concludes with an overview of the potential of both chelation and antioxidant therapy and outlines some perspectives for the future.

MANAGEMENT OF PARKINSON'S DISEASE: Strategies, pitfalls, and future directions A concise overview of clinical diagnosis, current therapeutic options, and ... neurodegeneration. (Postgraduate Medicine)
by JTE Multimedia

As the population ages, the incidence of Parkinson's disease is likely to increase. Unfortunately, the diagnosis can be complex, and current treatment options offer symptomatic relief in many patients but no cure for the underlying neurodegeneration. In this article, Dr Hermanowicz offers a concise overview of possible etiologic factors, clinical features, treatment principles and practice, and new therapeutic approaches that may improve management of Parkinson's disease in the future.

Original Publication Date: December 2001

Neurodegeneration: Methods and Protocols (Methods in Molecular Biology)
by Giovanni Manfredi (Editor), Hibiki Kawamata (Editor)

Neurodegenerative disorders, such as Alzheimer's and Parkinson's disease are a growing burden on our society. Understanding and treating these common diseases is one of the major current challenges for the biomedical field. In Neurodegeneration: Methods and Protocols, experts in the field tackle this challenge and present cutting-edge analytical and technological approaches to study the mechanisms underlying neurodegenerative processes. Organizes into five sections, chapters detail protocols for isolating and culturing cells from the nervous system, production and use of animal models, characterization of cell death, analytical tools to study disease mechanisms, and therapeutic approaches for neurodegeneration. Written in the successful Methods in Molecular Biology™ series format,...

Hormones in Neurodegeneration, Neuroprotection, and Neurogenesis
by Achille G. Gravanis (Editor), Synthia H. Mellon (Editor)

As life expectancy increases and population ages, the already enormous impact of neurodegeneration on society will become even larger without better prevention and treatment. Developing strategies to prevent degeneration of neurons and to promote a healthy nervous system is, thus, critical. The development of pharmacological agents that would increase production of new neurons was recently facilitated by the identification of the hormonal regulators of various steps of adult neurogenesis.
Written by a group of top world experts involved in the study of the mechanisms of hormonal control of brain damage and repair, this book gives a comprehensive account of the neuroprotective and neurogenic effects of steroid and polypeptide hormones. It discusses the effects of thyroid and steroid...

Frontiers in Clinical Neuroscience: Neurodegeneration and Neuroprotection (Advances in Experimental Medicine and Biology)
by Laszlo Vecsei (Editor)

This is a special proceedings - "Frontiers in Clinical Neuroscience: 2002" - held in Abel Lajtha's honor. Professor Lajtha is a well-known supporter of Hungarian science and he is celebrating his 80th birthday this year. Professor Vecsei is the secretary for the European Society for Clinical Neuropharmacology and the Danube Symposium for Neurological Sciences. The proceedings will focus on neurodegeneration and neuroprotection, two current topics in clinical and experimental neuroscience.

Bioimaging in Neurodegeneration (Contemporary Neuroscience)
by Patricia A. Broderick (Editor), David N. Rahni (Editor), Edwin H. Kolodny (Editor)

An authoritative survey of the cutting-edge imaging technologies available for diagnosing, treating, and discovering the underlying causes of Parkinson's and Alzheimer's disease, epilepsy, and leukodystrophy. The new technologies demonstrated include new sequences for magnetic resonance imaging (MRI), such as magnetization-prepared rapid acquisition gradient echo (MPRAGE); proton magnetic resonance spectroscopy (1H MRS); new tracers for positron emission tomography (PET) and single-photon emission tomography (SPECT), such as tropane analogs and altropane; neuromolecular imaging (NMI) of neurotransmitters directly in brain synapses of epilepsy patients with unique carbon-based electrochemical sensors; and intrinsic optical signal imaging (IOS), useful in diagnosing "spreading epileptiform...

Glaucoma: An Open-Window to Neurodegeneration and Neuroprotection (Progress in Brain Research, Vol. 173)
by Carlo Nucci (Editor), Luciano Cerulli (Editor), Neville N. Osborne (Editor), Giacinto Bagetta (Editor)

Glaucoma is one of the main causes of blindness throughout the world. It is characterized by death of the retinal ganglion cells, which is associated with loss of the axons making up the optic nerve. Recent studies have demonstrated support for the classification of glaucoma as a degenerative disease of the central nervous system (CNS). The search for treatment modalities that are effective for all patients with glaucoma has resulted in numerous studies aimed at identifying neuroprotection strategies for the treatment of this disease, like those used for other degenerative diseases of the CNS.

The present book will provide an in-depth examination of the most recent findings regarding glaucoma, including risk factors, diagnosis, clinical monitoring, treatment, and above all, the...

Metallochemistry of Neurodegeneration: Biological, Chemical and Genetic Aspects
by Henryk Kozlowski (Author), David R Brown (Author), Gianni Valensin (Author)

Bioinorganic chemistry has a cross disciplinary approach, applying the principles of chemistry to biological systems. Metallochemistry of Neurodegeneration: Biological, Chemical and Genetic Aspects discusses the rapidly developing area of metals in the nervous system and their role in neurodegenerative disease, such as Alzheimer's, Parkinson's and prion diseases. Written by leading experts in their fields, each chapter combines elements of genetics, biochemistry and biological inorganic chemistry in its discussion. The book highlights the differences in pathologies of neurodegenerative diseases but also discusses the mechanistic similarities. Sections include: metal ions and prion diseases; metal ions and Alzheimer disease; manganese in brain functioning; metal involvement in...

Neurodegeneration in Multiple Sclerosis (Topics in Neuroscience)
by M. Filippi (Editor), M. Rovaris (Editor), G. Comi (Editor)

Written by world-renowned scientists, the volume provides a state-of-the-art on the most recent MRI techniques related to MS, and it is an indispensable tool for all those working in this field. The context in which this book exists is that there is an increasing perception that modern MR methodologies should be more extensively employed in clinical trials to derive innovative information.